 HEIDELBERG, Germany, May 12, 2022 GLOBE NEWSWIRE -- Affimed N.V. Nasdaq: AFMD Affimed, or the Company, a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an upcoming poster presentation demonstrating the cytotoxic potential of its CD123CD16A-targeting innate cell engager ICE AFM28 at the Annual Meeting of the European Hematology Association EHA to be held in Vienna, Austria on June 9 - 12, 2022. 